Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years with acute myeloid leukaemia (AML). More-recent randomized trials demonstrate that low doses of gemtuzumab added to cytarabine and anthracycline-based chemotherapy benefit patients with better-risk AML.
Key Points
The addition of a low dose of gemtuzumab ozogamicin to cytarabine and anthracycline-based induction and consolidation chemotherapy improves survival in patients with more-favourable-risk acute myeloid leukaemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kern, W. & Estey, E. H. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 107, 116–124 (2006).
Willemze, R. et al. High dose (HD-AraC) vs. standard dose cytosine arabinoside (SD-AraC) during induction and IL-2 vs. observation after consolidation/autologous stem cell transplantation in patients with acute myelogenous leukemia (AML): Final report of the AML-12 trial of EORTC and GIMEMA Leukemia groups on the value of high dose AraC [abstract]. Blood 118, a257 (2011).
Löwenberg, B. et al. Cytarabine dose for acute myeloid leukemia. N. Engl. J. Med. 364, 1027–1036 (2011).
Bloomfield, C. D. et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58, 4173–4179 (1998).
Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361, 1249–1259 (2009).
Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet http://dx.doi.org/10.1016/S0140–6736(12)60485–1.
Petersdorf, S. et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood 114, a790 (2009).
Burnett, A. K. et al. Identification of patients with acute myeloblastic leukaemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J. Clin. Oncol. 29, 369–377 (2011).
Delaunay, J. et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract]. Blood 118, a79 (2011).
Burnett, A. K. et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial [abstract]. Blood 118, a582 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ravandi, F., Kantarjian, H. Gemtuzumab ozogamicin in acute myeloid leukaemia. Nat Rev Clin Oncol 9, 310–311 (2012). https://doi.org/10.1038/nrclinonc.2012.83
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.83
This article is cited by
-
New drug approvals in oncology
Nature Reviews Clinical Oncology (2020)
-
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare
British Dental Journal (2015)
